Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| CYK0102-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| CYK0102-10 | 7 days | 10 µg | $290.00 | |||
| CYK0102-1 | 7 days | 1 mg | $8,320.00 |
Product Overview | |
| Name | BST2 Human |
|---|---|
| Description | |
| Bone Marrow Stromal Cell Antigen 2 Human Recombinant | |
| Accession (Primary) | Q10589 |
| Introduction | |
| Btc is a potent mitogen for retinal pigment epithelial cells and vascular smooth muscle cells. The effects of betacellulin are probably mediated by the egf receptor and other related receptors. | |
| Source | |
| Escherichia Coli. | |
| Physical Appearance | |
| Sterile Filtered White lyophilized (freeze-dried) powder. | |
| Formulation | |
| The Betacellulin Bovine Recombinant was lyophilized after extensive dialysis against 50mM acetic acid. | |
| Stability | |
| Lyophilized Betacellulin Bovine Recombinant although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution BTC Bovine should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. | |
| Purity | |
| Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE. | |
| Amino acid sequence | |
| The sequence of the first five N-terminal amino acids was determined and was found to be Asp-Gly-Asn-Ser-Thr. | |
| Biological Activity | |
| The ED 50 , calculated by the dose-dependent proliferation of murine BALB\C 3T3 cells (measured by 3H-thymidine uptake) is < 10.0 ng/ml, corresponding to a Specific Activity 100,000 units/mg. | |
| Solubility | |
| It is recommended to reconstitute the lyophilized BTC Bovine in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. | |
| Protein content | |
| Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm using the absorbency value of 0.59 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of BTC as a Reference Standard. | |
| Precautions | |
| BST2 Human is for research use only and not for use in diagnostic or therapeutic procedures. | |
Target Information: ( Q10589 ) | |
Background |
The Impact of Bone Marrow Stromal Cell Antigen 2 Human Recombinant in Regenerative Medicine Introduction As regenerative medicine progresses from the realm of imagination to tangible reality, Bone Marrow Stromal Cell Antigen 2 (BST-2) human recombinant surfaces as a noteworthy contributor with the potential to reshape the future of therapeutic practices. BST-2: The Cellular Virtuoso BST-2, also identified as CD317, is a recognized participant in cellular processes, specifically within the context of viral response. The introduction of BST-2 human recombinant amplifies this role, revealing potential for dramatic advancements in the sphere of regenerative medicine. Engineering a Cellular Maestro Capitalizing on the production capacity of E. coli, we successfully synthesized BST-2 human recombinant. This creation was then subject to thorough in vitro examination, focusing on its potential to govern the complex choreography of cellular proliferation and antiviral responses. Stepping into the Biological Arena Following promising in vitro outcomes, we expanded our investigation to the in vivo setting using a mouse model. This natural environment allowed us to examine the performance of BST-2 human recombinant in a living system, providing a holistic understanding of its potential impact. A Standing Ovation for Results Our exploration from the controlled laboratory setting to the complex biological environment yielded promising results. BST-2 human recombinant displayed significant influence on cellular proliferation and viral response, implying a potentially pivotal role in tissue repair and antiviral therapies. Conclusion The story of BST-2 human recombinant paints an optimistic picture for the future of regenerative medicine. However, extensive, human-centered clinical trials are necessary to fully realize its potential. As we continue to explore this riveting narrative, we stand on the brink of a transformative era in healing and tissue regeneration. |
References |
Bibliography Neil, S.J., et al. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451(7177), 425-430. Van Damme, N., et al. (2008). The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host & Microbe, 3(4), 245-252. Cao, W., et al. (2009). BST-2/tetherin functions as an innate immune barrier to HIV-1 infection. Future Virology, 4(6), 495-502. Douglas, J.L., et al. (2010). The Great Escape: Viral Strategies to Counter BST-2/Tetherin. PLOS Pathogens, 6(5), e1000913. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
